呋喃并[3,4-d]嘧啶 | 271-05-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 呋喃并[3,4-d]嘧啶
• 英文名称: Furo[3,4-d]pyrimidine
• CAS: 271-05-6
• 化学式: C₆H₄N₂O
• 分子量: 120.11
• InChiKey: WGBWKGXFYKPJOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PRMT5 CONTENANT UNE DIHYDRO- OU TÉTRAHYDRO-ISOQUINOLÉINE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100730A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• [EN] ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'ARGININE MÉTHYLTRANSFÉRASE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2016044626A1

  公开（公告）日：2016-03-24

  Described herein are compounds of Formula (S-I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

  本文描述了式（S-I）的化合物，其药用盐以及药物组合物。本文描述的化合物对抑制精氨酸甲基转移酶活性有用。还描述了利用这些化合物治疗精氨酸甲基转移酶介导的疾病的方法。
• Pyrimidine, quinazoline, pteridine and triazine derivatives
  申请人：Binggeli Alfred

  公开号：US20070225271A1

  公开（公告）日：2007-09-27

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A，R1至R5和G如描述和声明中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100734A1

  公开（公告）日：2014-06-26

  Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组成物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• HETERO-FUSED CYCLIC COMPOUND
  申请人：EISAI R&D MANAGEMENT CO., LTD.

  公开号：US20160168176A1

  公开（公告）日：2016-06-16

  A compound represented by the formula (I) or a salt thereof: wherein a ring Z is a 5 to 6-membered heteroaromatic ring having one or two heteroatoms in the ring; X 1 is a hydrogen atom, a hydroxy group, a hydroxy C 1-6 alkyl group, —B(OH) 2 , a boronate ester group, a cyclic boronate ester group, a boranyl group, a cyclic boranyl group, —BF 3 M n1 , —Sn(R 12 )(R 13 )(R 14 ), a leaving group, a carboxy group, a formyl group, or —NR 16 R 17 ; and X 2 is a hydrogen atom or —CO 2 R 18 .

  一个由化学式(I)表示的化合物或其盐：其中环Z是一个具有一个或两个杂原子的5到6元杂芳香环；X1是氢原子、羟基、羟基C1-6烷基基团、—B(OH)2、硼酸酯基团、环硼酸酯基团、硼烷基团、环硼烷基团、—BF3Mn1、—Sn(R12)(R13)(R14)、一个离去基团、一个羧基、一个甲酰基，或—NR16R17；而X2是氢原子或—CO2R18。